Clinical Trials List
2020-02-28 - 2023-08-04
Phase II
Not yet recruiting6
ICD-10C67.0
Malignant neoplasm of trigone of bladder
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.0
Malignant neoplasm of trigone of urinary bladder
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Ching-Chia Li Division of Urology
- Tsung-Yi Huang Division of Urology
- Yung-Chin Lee Division of Urology
- Hung-Lung Ke Division of Urology
- Tsu-Ming Chien Division of Urology
- Hsiang Ying Lee Division of Urology
- 黃俊農 Division of Urology
- 阮雍順 Division of Urology
- Sheng-Chen Wen Division of Urology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- YU-CHUAN LU 未分科
- Yeong-Shiau Pu 未分科
- JIAN-HUA HONG 未分科
- YEN-HENG LIN Division of Radiology
- - - 未分科
- 陳慶達 Division of Ophthalmology
- PO-MING CHOW 未分科
- 王中傑 Division of Others
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Kai-Jie Yu Division of Hematology & Oncology
- Rita cheng 未分科
- Po-Jung Su Division of Hematology & Oncology
- 林柏宏 未分科
- 沈鼎文 Division of Radiology
- I-hung Shao 未分科
- 譚欣媛 Division of Ophthalmology
- 黃亮鋼 Division of Urology
- Hong-Cheng Gan 未分科
- See-Tong Pang 未分科
- Yuan-Cheng Chu 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Yi-Huei Chang 未分科
- Chi-Rei Yang 未分科
- Hsi-Chin Wu Division of Urology
- Chi-Ping Huang 未分科
- Po-Fan Hsieh 未分科
- Chao-Hsiang Chang 未分科
- Yu-De Wang 未分科
- 陳冠亨 未分科
- Po-Jen Hsiao 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Cheng-Che Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Tzu-chun Wei Division of Urology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
280 participants
